NDRANasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
ENDRA Life Sciences Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$4.75+0.01 (+0.21%)
Close on Oct 19, 2026
- Market cap
- $11.76M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.38 (−22.51%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $11.76M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.86
- Dividend yield
- –
- Free cash flow yield
- -44.23%
Fundamentals
- Net income
- -$5.92M
- EPS, diluted
- -$5.98
- Free cash flow
- -$5.20M
- Book value per share
- $2.55
- Diluted shares
- 2M
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$6.65M
Net income
-$5.92M
EPS, diluted
-$5.98
Free cash flow
–
Reported periodTrailing twelve months